Premium
Severe Infusion‐Related Reaction to Liposomal Amphotericin B
Author(s) -
Wilson Rachael K,
Connolly Michael J,
Harrup Rosemary A
Publication year - 2013
Publication title -
journal of pharmacy practice and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.222
H-Index - 22
eISSN - 2055-2335
pISSN - 1445-937X
DOI - 10.1002/j.2055-2335.2013.tb00217.x
Subject(s) - medicine , neutropenia , amphotericin b , adverse effect , fusarium solani , voriconazole , chemotherapy , surgery , antifungal , dermatology , microbiology and biotechnology , biology
Aim To describe a case of severe infusion‐related reaction to liposomal amphotericin B (LAB). Clinical details A severely immunocompromised 58‐year‐old male with acute myeloid leukaemia experienced 2 infusion‐related adverse events when treated with LAB for a localised Fusarium solani fungal infection of the right forefoot. The initial adverse reaction to LAB was not serious. However, the second adverse reaction following a re‐challenge was serious. The patient had a poor prognosis because of the likelihood of further chemotherapy‐induced neutropenia and a potentially untreated disseminated fungal infection in light of planned chemotherapy. Outcomes LAB was successfully substituted with conventional amphotericin B to treat Fusarium solani infection. No adverse events were observed with conventional amphotericin B. Conclusion The patient is suspected to have had a reaction to the lipid carrier of LAB.